Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
WARFARIN SODIUM vs Warfarin
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), preventing reduction of vitamin K, thereby impairing activation of clotting factors II, VII, IX, X, and anticoagulant proteins C and S.
Warfarin inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of functional clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement,Reduced risk of death, recurrent myocardial infarction, and thromboembolic events after myocardial infarction
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation,Prophylaxis and treatment of thromboembolic complications associated with prosthetic heart valves,Reduction of risk of death, recurrent myocardial infarction, and thromboembolic events after myocardial infarction (off-label: prevention of stroke in patients with antiphospholipid syndrome, treatment of peripheral artery disease)
2.5-10 mg orally once daily, adjusted based on INR; typical maintenance dose 2-7.5 mg/day.
Oral, 2-10 mg once daily adjusted based on INR, with a loading dose of 5-10 mg for 1-3 days in acute anticoagulation.
Terminal elimination half-life is approximately 20-60 hours (mean 40 hours) for the S-enantiomer and 37-89 hours for the R-enantiomer. The clinical context: anticoagulant effect persists for 2-5 days due to the half-life of clotting factors (II, VII, IX, X), with factor VII (half-life ~6h) being the first affected; full effect requires 3-5 days to achieve steady-state.
Terminal half-life: 40 hours (range 20–60 hours); clinical context: long half-life causes delayed onset and prolonged duration, leading to 3–5 days to steady state.
Primarily hepatic via CYP2C9 (major), with contributions from CYP3A4, CYP1A2, CYP2C19, and CYP2C8. Metabolites are excreted in urine and feces.
Hepatic metabolism primarily via CYP2C9 (major), with contributions from CYP3A4, CYP1A2, and CYP2C19. Warfarin is a racemic mixture: S-warfarin (more potent) is metabolized by CYP2C9; R-warfarin is metabolized by CYP1A2, CYP3A4, and CYP2C19.
Primarily renal as inactive metabolites (92%), with minimal biliary/fecal (8%). The S-enantiomer is metabolized by CYP2C9 to inactive metabolites; the R-enantiomer is metabolized by CYP1A2 and CYP3A4. Less than 2% is excreted unchanged in urine.
Renal: approximately 92% as inactive metabolites (conjugated and unconjugated); biliary/fecal: approximately 8% as minor metabolites.
Primarily bound to albumin (97-99%). The free fraction is the pharmacologically active moiety.
99% bound to albumin.
Approximately 0.14 L/kg. This low Vd indicates limited extravascular distribution, consistent with high protein binding and confinement to the vascular space, primarily binding to albumin.
Vd: 0.14 L/kg (range 0.11–0.2 L/kg); clinical meaning: low volume indicates high protein binding and limited tissue distribution.
Oral: >95% (immediate-release tablets). Warfarin has complete absorption from the gastrointestinal tract. Food can delay but does not significantly reduce absorption.
Oral: 100% (practically complete absorption).
No dose adjustment required based on GFR; warfarin is highly protein bound and not renally cleared. Monitor INR closely in renal impairment due to altered protein binding.
No dose adjustment required for renal impairment; however, warfarin is highly protein-bound and volume of distribution may decrease with severe renal impairment, requiring closer INR monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50% and monitor INR closely; Child-Pugh C: avoid use or use extreme caution with dose reduction >50%.
Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50% and monitor INR closely; Child-Pugh C: Contraindicated due to impaired synthesis of clotting factors and increased bleeding risk.
Initial dose 0.1-0.2 mg/kg orally once daily (max 5 mg); adjust based on INR; typical maintenance 0.05-0.34 mg/kg/day.
Initial dose 0.2 mg/kg orally once daily; maintenance dose adjusted to target INR of 2.0-3.0, typically 0.1 mg/kg once daily; maximum initial dose 5 mg.
Start with lower initial dose (2-3 mg/day) due to increased sensitivity; adjust cautiously; frequent INR monitoring recommended.
Start with lower doses (2-5 mg orally once daily) due to increased sensitivity and risk of bleeding; monitor INR more frequently, especially at initiation and after any dose changes.
Warfarin can cause major or fatal bleeding. Risk factors include INR >4, age, comorbidities, and drug interactions. Patients should be monitored regularly for INR. Use cautiously with conditions that increase bleeding risk.
Warfarin can cause major or fatal bleeding. Monitor INR regularly and adjust dose to maintain therapeutic level. Risk factors include age, renal impairment, comorbidities, and concomitant medications. Instruct patients on signs of bleeding. Concomitant use of NSAIDs, aspirin, or other anticoagulants increases bleeding risk.
Risk of hemorrhage; monitor INR frequently. Necrosis or gangrene of skin or other tissues due to protein C deficiency. Systemic atheroemboli (purple toes syndrome). Acute kidney injury (warfarin-related nephropathy). Pregnancy: crosses placenta, causing fetal hemorrhage and spontaneous abortion.
Hemorrhage: major or fatal bleeding; monitor INR closely,Necrosis/skin necrosis: rare, due to protein C deficiency; discontinue if suspected,Systemic atheroemboli/cholesterol emboli: purple toe syndrome,Pregnancy: can cause fetal harm; contraindicated except in high-risk mechanical valves (category X),Hepatic impairment: increased INR response,Renal impairment: increased bleeding risk,Elderly: increased sensitivity,Drug interactions: numerous (e.g., NSAIDs, antibiotics, antifungals, antiplatelets, statins, certain foods like cranberry juice, and vitamin K)
Hypersensitivity to warfarin or any component; hemorrhagic tendencies (e.g., hemophilia, thrombocytopenia); recent or potential surgery; active bleeding; severe uncontrolled hypertension; pregnancy; major regional or lumbar block anesthesia; unreliable patient with inability to monitor INR.
Active bleeding or hemorrhagic tendencies (e.g., hemophilia, thrombocytopenia),Hypersensitivity to warfarin or any component,Recent or contemplated surgery of the central nervous system or eye,Malignant hypertension,Bacterial endocarditis,Pregnancy (except in women with mechanical heart valves at high risk for thromboembolism),Lack of reliable monitoring or patient noncompliance,Severe hepatic impairment (relative),Unsupervised spinal puncture or diagnostic procedures with potential for bleeding
Avoid or maintain consistent intake of foods high in vitamin K: liver, leafy greens (e.g., spinach, kale, Swiss chard, collard greens, turnip greens, beet greens), broccoli, Brussels sprouts, cabbage, asparagus, green tea, soybean oil, canola oil, and certain legumes. Avoid large amounts of cranberry juice, grapefruit juice, and pomegranate juice. Limit alcohol consumption. Vitamin K supplements should only be taken under medical supervision.
Foods high in vitamin K (e.g., kale, spinach, collard greens, Swiss chard, parsley, Brussels sprouts, broccoli, green tea) can antagonize warfarin effect; maintain consistent intake. Cranberry juice, grapefruit juice, and alcohol (especially binge drinking) may potentiate effect. Avoid large amounts of avocado, mango, and certain herbal supplements (e.g., ginseng, ginkgo, St. John's wort, coenzyme Q10).
Warfarin sodium is teratogenic. First trimester exposure is associated with warfarin embryopathy (nasal hypoplasia, stippled epiphyses) in 5-30% of exposed fetuses. Second and third trimester exposure can cause CNS abnormalities, optic atrophy, microcephaly, mental retardation, and fetal hemorrhage. Risk is highest between weeks 6 and 12 of gestation.
First trimester: Warfarin is associated with a characteristic embryopathy (fetal warfarin syndrome) occurring in 5-30% of exposed fetuses, including nasal hypoplasia, stippled epiphyses, and central nervous system abnormalities. Second and third trimesters: Risk of fetal hemorrhage, including intracranial bleeding, and spontaneous abortion. Use is contraindicated in pregnancy due to fetal risks; heparin or low molecular weight heparin preferred.
Warfarin is excreted into breast milk in negligible amounts. The M/P ratio is approximately 0.2. It is considered compatible with breastfeeding, but monitor infant for bruising or bleeding.
Warfarin is excreted into breast milk in minimal amounts; M/P ratio is approximately 0.37. No adverse effects reported in nursing infants. Considered compatible with breastfeeding by the American Academy of Pediatrics, but monitor infant for signs of bleeding.
Pregnancy increases warfarin clearance due to elevated clotting factors and increased plasma volume. Dose requirements may increase by 20-50% to maintain therapeutic INR. Close INR monitoring and dose adjustments are necessary throughout pregnancy, especially during the second and third trimesters.
Pregnancy is a hypercoagulable state; warfarin requirements may increase due to increased plasma volume, hepatic metabolism, and vitamin K-dependent clotting factor synthesis. Dose adjustments often needed based on INR targets, which are typically higher (e.g., 2.5-3.5) for mechanical heart valves. However, warfarin is generally avoided in pregnancy and replaced with heparin or LMWH.
Initiate warfarin at 5 mg/day for most patients, adjusting based on INR. Avoid loading doses. Monitor INR at least weekly during initiation. CYP2C9 and VKORC1 genotyping can guide dosing. Administer at same time daily, preferably in evening. For urgent reversal, use 4-factor PCC (Kcentra) or FFP. Vitamin K 1-2 mg PO for non-urgent INR elevation. Beware of drug interactions that potentiate (e.g., amiodarone, fluconazole) or inhibit (e.g., carbamazepine, rifampin) warfarin. Use with caution in hepatic impairment and renal disease.
Monitor INR closely, especially when initiating, discontinuing, or changing doses of interacting drugs. Avoid intramuscular injections due to bleeding risk. Warfarin has a narrow therapeutic index and requires regular INR monitoring (target usually 2-3 for most indications). Consider pharmacogenetic testing for CYP2C9 and VKORC1 variants to guide dosing. Use with caution in patients with renal or hepatic impairment. Vitamin K can reverse effects; consider low-dose vitamin K for over-anticoagulation without major bleeding.
Take warfarin exactly as prescribed, at the same time each day.,Do not skip doses or double up if you miss a dose; contact your doctor for instructions.,Regular blood tests (INR) are required to ensure the dose is correct.,Avoid alcohol and consult doctor before starting or stopping any medications, including over-the-counter drugs and supplements.,Report any unusual bleeding or bruising, dark/tarry stools, blood in urine, coughing up blood, severe headache, or weakness immediately.,Use a soft toothbrush, electric razor, and be cautious with sharp objects to minimize bleeding risk.,Wear a medical alert bracelet and carry a card stating you take warfarin.,Do not change your diet significantly, especially foods high in vitamin K (e.g., spinach, kale, broccoli, Brussels sprouts) – maintain consistent intake.,If you are pregnant or plan to become pregnant, discuss with doctor; warfarin can harm the fetus.,Limit cranberry juice, green tea, and certain herbal supplements (e.g., ginseng, St. John's wort, ginkgo) as they may affect INR.
Take warfarin exactly as prescribed, typically once daily at the same time.,Avoid making significant changes to your diet, especially foods high in vitamin K (e.g., leafy greens, broccoli, Brussels sprouts).,Do not start or stop any other medications, including over-the-counter drugs, herbal supplements, or vitamins, without consulting your doctor.,Report any unusual bleeding or bruising, dark/tarry stools, blood in urine, or severe headache to your healthcare provider.,Use a soft toothbrush and electric razor to minimize bleeding risk.,Carry a medical ID or card indicating you are taking warfarin.,Keep all appointments for INR blood tests.,Avoid alcohol consumption or limit to minimal amounts.,If a dose is missed, take it as soon as remembered on the same day; do not double the next day's dose. Contact doctor if unsure.
"Estradiol (estrogen) may reduce the anticoagulant effect of warfarin, likely by enhancing the synthesis of clotting factors (e.g., factors II, VII, IX, X) in the liver. This interaction can lead to a decrease in the International Normalized Ratio (INR) and potentially increase the risk of thromboembolic events. Conversely, when estradiol is discontinued, warfarin's effect may increase, raising the risk of bleeding."
"Warfarin exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase, thereby reducing the synthesis of clotting factors II, VII, IX, and X. Cefradine, a first-generation cephalosporin, can potentiate the effect of warfarin through two mechanisms: it may eliminate gut flora that produce vitamin K, leading to reduced vitamin K availability, and it may directly inhibit the hepatic metabolism of warfarin. The combined effect can result in an elevated international normalized ratio (INR) and an increased risk of bleeding, which may manifest as hematuria, ecchymosis, or gastrointestinal hemorrhage."
"Warfarin, a vitamin K antagonist, exerts its anticoagulant effect by inhibiting the synthesis of vitamin K-dependent clotting factors. Oxymetholone, an anabolic steroid, can potentiate the effect of warfarin by reducing the metabolism of warfarin through inhibition of cytochrome P450 enzymes (specifically CYP2C9) and by decreasing the synthesis and turnover of clotting factors, leading to an increased International Normalized Ratio (INR) and a heightened risk of bleeding. This interaction may result in clinically significant hemorrhage if not properly monitored and managed."
"Estradiol (estrogen) may reduce the anticoagulant effect of warfarin, likely by enhancing the synthesis of clotting factors (e.g., factors II, VII, IX, X) in the liver. This interaction can lead to a decrease in the International Normalized Ratio (INR) and potentially increase the risk of thromboembolic events. Conversely, when estradiol is discontinued, warfarin's effect may increase, raising the risk of bleeding."
"Warfarin exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase, thereby reducing the synthesis of clotting factors II, VII, IX, and X. Cefradine, a first-generation cephalosporin, can potentiate the effect of warfarin through two mechanisms: it may eliminate gut flora that produce vitamin K, leading to reduced vitamin K availability, and it may directly inhibit the hepatic metabolism of warfarin. The combined effect can result in an elevated international normalized ratio (INR) and an increased risk of bleeding, which may manifest as hematuria, ecchymosis, or gastrointestinal hemorrhage."
"Warfarin, a vitamin K antagonist, exerts its anticoagulant effect by inhibiting the synthesis of vitamin K-dependent clotting factors. Oxymetholone, an anabolic steroid, can potentiate the effect of warfarin by reducing the metabolism of warfarin through inhibition of cytochrome P450 enzymes (specifically CYP2C9) and by decreasing the synthesis and turnover of clotting factors, leading to an increased International Normalized Ratio (INR) and a heightened risk of bleeding. This interaction may result in clinically significant hemorrhage if not properly monitored and managed."
Common clinical questions about WARFARIN SODIUM vs Warfarin, answered by our medical review team.
WARFARIN SODIUM is a Anticoagulant (Vitamin K Antagonist) that works by Inhibits vitamin K epoxide reductase complex 1 (VKORC1), preventing reduction of vitamin K, thereby impairing activation of clotting factors II, VII, IX, X, and anticoagulant proteins C and S.. Warfarin is a Anticoagulant (Vitamin K Antagonist) that works by Warfarin inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of functional clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between WARFARIN SODIUM and Warfarin depend on the specific clinical indication. These are both Anticoagulant (Vitamin K Antagonist) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of WARFARIN SODIUM is: 2.5-10 mg orally once daily, adjusted based on INR; typical maintenance dose 2-7.5 mg/day.. The standard adult dose of Warfarin is: Oral, 2-10 mg once daily adjusted based on INR, with a loading dose of 5-10 mg for 1-3 days in acute anticoagulation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining WARFARIN SODIUM and Warfarin. Estradiol (estrogen) may reduce the anticoagulant effect of warfarin, likely by enhancing the synthesis of clotting factors (e.g., factors II, VII, IX, X) in the liver. This interaction can lead to a decrease in the International Normalized Ratio (INR) and potentially increase the risk of thromboembolic events. Conversely, when estradiol is discontinued, warfarin's effect may increase, raising the risk of bleeding. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. WARFARIN SODIUM is classified as Category D/X. Warfarin sodium is teratogenic. First trimester exposure is associated with warfarin embryopathy (nasal hypoplasia, stippled epiphyses) in 5-30% of exposed fetuses. Second and thir. Warfarin is classified as Category D/X. First trimester: Warfarin is associated with a characteristic embryopathy (fetal warfarin syndrome) occurring in 5-30% of exposed fetuses, including nasal hypoplasia, stippled epip. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.